News | January 12, 2010

Endothelial Function Test Named a Top Medical Breakthrough

January 12, 2010 – In its January issue, Prevention magazine named the Endo-PAT2000 endothelial function testing device one of the top medical breakthroughs of 2009.

The American Heart Association said 50 percent of coronary deaths occur in people with no previous symptoms, but a study by the Mayo Clinic suggests measuring endothelial function can aid diagnosis. The seven-year Mayo Clinic and Tufts-New England Medical Center study published in April 2009 found the measuring vessel health can help diagnosis a variety of medical conditions, including coronary artery disease, heart attack, stroke, sleep apnea, pre-eclamptic toxemia, and erectile dysfunction.

The study suggests a patient with low risk (based on Framingham Risk Score) but high endothelial dysfunction is 300 percent more likely to have a heart attack than a patient with low risk and no endothelial dysfunction. In the study, 49 percent of patients whose Endo-PAT test indicated poor endothelial function had a cardiac event during the seven-year study.

Amir Lerman, M.D., a cardiologist at the Mayo Clinic, explained that a “poor score is a stronger warning than the usual risk factors, because it indicates that cardiovascular disease has already begun – but at an early stage when you can more easily control your risks.”

The medical technology company Medvica International is among the first companies to market the Endo-PAT2000 in North America. The device uses sensors that measure blood flow through a patient’s fingers. Endothelial cells line the inner walls of blood vessels, lymph vessels, and the heart, and damage to them may be an early sign of heart disease. The device is small enough to sit on a table for office-based use. The test takes 15-minutes.

Endo-PAT testing is reimbursable by Medicare and covered by most major U.S. insurance companies.

For more information: www.medvica.com

Related Content

Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
High Intensity Exercise in Teenagers Could Ward Off Heart Disease

Ultrasound image of the carotid artery. Lines in yellow were used to determine arterial diameter and stretching before and following exercise.

News | Cardiac Diagnostics | July 16, 2018
New research published in Experimental Physiology has indicated potential differences in heart health benefits of...
News | Cardiac Diagnostics | June 14, 2018
A team of researchers says it has linked sensitivity to an allergen in red meat to the buildup of plaque in the...
The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

 

Feature | Cardiac Diagnostics | May 07, 2018 | Steven D. Freedman, M.D., Ph.D.
 
Overlay Init